Company Information

LAURUS LABS LTD.

NSE : LAURUSLABSBSE : 540222ISIN CODE : INE947Q01028Industry : Pharmaceuticals & DrugsHouse : Private
BSE426.25-5.45 (-1.26 %)
PREV CLOSE ( ) 431.70
OPEN PRICE ( ) 429.85
BID PRICE (QTY) 0.00 (0)
OFFER PRICE (QTY) 0.00 (0)
VOLUME 83360
TODAY'S LOW / HIGH ( )423.20 431.45
52 WK LOW / HIGH ( )279.65 470.9
NSE426.50-4.9 (-1.14 %)
PREV CLOSE( ) 431.40
OPEN PRICE ( ) 429.50
BID PRICE (QTY) 0.00 (0)
OFFER PRICE (QTY) 426.50 (145)
VOLUME 1487447
TODAY'S LOW / HIGH( ) 423.50 431.30
52 WK LOW / HIGH ( )278.85 471
ChairmanMalempati Venugopala Rao
Company SecretaryG Venkateswar Reddy
Executive DirectorVenkata Ravi Kumar Vantaram
Lakshmana Rao CV
Non Executive Independent DirectorAruna Bhinge
Rajesh Koshy Chandy
Ravindranath Kancherla
Whole Time DirectorSatyanarayana Chava
Incorporation Year : 19-09 2005

Registered Office :

Address : Laurus Enclave, Plot Office 01,Edulapakabonangi Village, Parawada,Mandal, Anakapalli Vishakhapatnam,
Andhra Pradesh-531021 .

Phone : 0891 3061222 / 6601222

Email :  info@lauruslabs.com 

Industry : Pharmaceuticals & Drugs

Listing : BSE,NSE

© NIRMAL BANG. All rights reserved

Designed , Developed & Content Powered by Accord Fintech Pvt. Ltd.

Open an Account
FOR AFREE *DEMAT & BROKING ACCOUNT

Please fill in the details below

Close X

(Note - You will receive a call from our sales executive)

CLOSE X

RISK DISCLOSURES ON DERIVATIVES

  • 9 out of 10 individual traders in equity Futures and Options Segment, incurred net losses.
  • On an average, loss makers registered net trading loss close to ₹ 50,000.
  • Over and above the net trading losses incurred, loss makers expended an additional 28% of net trading losses as transaction costs.
  • Those making net trading profits, incurred between 15% to 50% of such profits as transaction cost.

Source:

1. SEBI study dated January 25, 2023 on “Analysis of Profit and Loss of Individual Traders dealing in equity Futures and Options (F&O) Segment”, wherein Aggregate Level findings are based on annual Profit/Loss incurred by individual traders in equity F&O during FY 2021-22.